Welcome to our dedicated page for DuPont de Nemours SEC filings (Ticker: DD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DuPont de Nemours, Inc. filings document the regulatory disclosures of a Delaware specialty materials company with common stock listed on the New York Stock Exchange under DD. Its 8-K reports cover operating and financial results, Regulation FD disclosures, material events, board composition changes, corporate-governance matters and capital-structure disclosures.
DuPont proxy materials describe annual stockholder voting matters, director elections, governance practices, executive compensation and proposals affecting the company’s certificate of incorporation and common stock. Recent filings also document separation-related matters, including disclosures connected with the completed Qnity Electronics spin-off, as well as agreements and percentage calculations tied to the post-separation corporate structure.
Amy G. Brady, a director of DuPont de Nemours, Inc. (DD), reported a non-derivative purchase of common stock on 08/29/2025. The Form 4 shows an acquisition of 105.6292 shares at a price of $76.92 per share, bringing her total reported beneficial ownership to 19,274.5372 shares, held directly. The filing includes a disclosure that the total includes shares acquired through dividend reinvestment. The filing was submitted with a signature dated 09/03/2025 by Peter W. Hennessey by power of attorney.
DuPont announced a definitive agreement to sell its Aramids business (Kevlar4 and Nomex4) to Arclin for an enterprise value of approximately $1.8 billion. Under the Transaction Agreement, DuPont will receive roughly $1.2 billion in pre-tax cash at closing (subject to customary adjustments), a $300 million note receivable, and a non-controlling common equity stake in the combined Arclin business currently valued at $325 million, expected to represent about a 17.5% ownership at closing. The agreement is conditioned on customary closing requirements, including regulatory approvals in multiple non-U.S. jurisdictions and satisfactory representations, warranties and performance by the parties.
DuPont agreed to sell its Aramids business (Kevlar® and Nomex®) to Arclin, a portfolio company of an affiliate of TJC, L.P., in a transaction valuing the business at approximately $1.8 billion. At closing DuPont is expected to receive approximately $1.2 billion in pre-tax cash proceeds (subject to customary adjustments), a $300 million note receivable, and a non-controlling common equity stake in the combined Arclin business currently valued at about $325 million (approximately 17.5% at closing). The sale is conditioned on customary closing conditions, including regulatory approvals. The information is disclosed in a press release embedded in the company’s 8-K filing.
Edward D. Breen, Executive Chair and director of DuPont de Nemours (DD), reported changes in his beneficial ownership of common stock. On 08/12/2025 he received 13,754 shares as annuity payments from prior 2021 GRATs and through dividend reinvestment, bringing his post-transaction holdings to 165,405.7751 shares. On 08/20/2025 he recorded a disposition of 28,111 shares related to funding a new GRAT (2025-7), leaving 137,294.7511 shares beneficially owned. The filing notes the 13,754 shares were received at no cash price and the 28,111 shares were disposed of at no cash price. The report was submitted by power of attorney.
DuPont de Nemours (DD) filed an 8-K describing contingent outcomes tied to a planned Spin-Off involving Qnity. The filing states that if the Spin-Off is not consummated by the earlier of March 31, 2026 or the date Qnity notifies parties that the Spin-Off will not occur, or if not completed within two business days of gross proceeds being released from escrow, then the Notes will be subject to a special mandatory redemption. The filing also states that the Unsecured Notes will be jointly and severally and unconditionally guaranteed on a senior unsecured basis by each Qnity subsidiary that is a borrower or guarantor under Qnity's Credit Facilities. The document is signed by Michael G. Goss, Vice President and Controller, dated August 15, 2025.
DuPont de Nemours announced that its wholly owned subsidiary, Qnity Electronics, priced an offering of debt securities consisting of $1.0 billion aggregate principal amount of 5.750% Senior Secured Notes due 2032 and $750 million aggregate principal amount of 6.250% Senior Notes due 2033. The Notes were priced at 100.000% of their principal amount and are being offered under Rule 144A and Regulation S.
The offering is being made in connection with DuPont's previously announced plan to separate its electronics business through a pro rata distribution of Qnity common stock to DuPont stockholders. The offering is expected to close on August 15, 2025, subject to customary closing conditions, and the Notes and related guarantees have not been registered under the Securities Act.
DuPont and its wholly owned subsidiary Qnity Electronics announced an offering of approximately $1.5 billion aggregate principal amount of senior secured notes and $1.0 billion aggregate principal amount of senior unsecured notes, to be offered under Rule 144A and Regulation S. The offering is being made in connection with DuPont's previously announced plan to separate its electronics business by distributing Qnity common stock pro rata to DuPont stockholders. A press release describing the offering is furnished as Exhibit 99.1 and is furnished, not filed, for certain Exchange Act purposes.
DuPont de Nemours, Inc. (DD) Q2-25 10-Q highlights
- Net sales rose 2.7% YoY to $3.26 bn; six-month sales up 3.6% to $6.32 bn.
- Continuing ops profitability improved: operating EPS (basic) $0.54 vs $0.40; operating income before tax $306 m vs $296 m.
- Discontinued ops drag: $168 m loss in Q2 and $202 m YTD tied largely to PFAS-related MOU and New Jersey litigation.
- Bottom line: Q2 net income fell 62% to $70 m; GAAP EPS $0.14 vs $0.43. 1H-25 shows $512 m loss, driven by a $768 m goodwill impairment on Aramids reporting unit.
- Cash flow: 1H operating cash $763 m (-25% YoY); capex $365 m; free cash flow ≈$398 m.
- Balance sheet: Cash $1.84 bn, debt $7.18 bn (ST & LT); equity $23.5 bn; net leverage ~0.2× EBITDA (company data).
- Strategic actions: targeting 1 Nov 2025 spin-off of ElectronicsCo (to be named Qnity Electronics); 2025 segment realignment now reports ElectronicsCo and IndustrialsCo separately.
- Restructuring: $49 m charges YTD for separation-related program (target $100 m through 2026); 2023-24 program largely complete.
- Legal & tax: PFAS cost-sharing and New Jersey matters continue; effective tax rate Q2 22.2% vs 40.5%.
Outlook: Management reiterates separation timeline; near-term focus on margin expansion, cash generation and litigation management.
On 3 Aug 2025 DuPont (NYSE: DD), Chemours and Corteva agreed to a Judicial Consent Order with the State of New Jersey to resolve all outstanding state claims tied to historic DNAPL, solvent and PFAS contamination at four legacy DuPont sites (Chambers Works, Parlin, Pompton Lakes, Repauno) and alleged statewide PFAS impacts.
Financial terms:
- A combined $875 million cash payment spread over 25 years; first instalment due no sooner than 31 Jan 2026.
- DuPont’s share is estimated at $311 million NPV; a $177 million pre-tax charge was recorded in Q2-25 discontinued operations.
- DuPont will apply its existing $35 million MOU escrow to the 2026 payment.
- DuPont & Corteva will post a separate $475 million surety-backed Reserve Fund to backstop remediation once site-level funding is exhausted.
Additional provisions: DuPont/Corteva will pay $150 million (DuPont $106.5 m) to buy Chemours’ rights to equal PFAS-related insurance proceeds plus a contingent fee. A third-party review could require higher remedial funding sureties, potentially increasing future environmental reserves. Parties may prepay at the settlement discount rate.
The agreement contains no admission of liability, remains subject to public comment and Federal District Court approval, and will offset each party’s annual PFAS MOU escrow obligations.